[go: up one dir, main page]

WO2016152054A1 - Effets de prévention et d'atténuation de la douleur du glycéride d'acide gras ω3 - Google Patents

Effets de prévention et d'atténuation de la douleur du glycéride d'acide gras ω3 Download PDF

Info

Publication number
WO2016152054A1
WO2016152054A1 PCT/JP2016/001259 JP2016001259W WO2016152054A1 WO 2016152054 A1 WO2016152054 A1 WO 2016152054A1 JP 2016001259 W JP2016001259 W JP 2016001259W WO 2016152054 A1 WO2016152054 A1 WO 2016152054A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
fatty acid
omega
acid
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2016/001259
Other languages
English (en)
Japanese (ja)
Inventor
忠広 対馬
芳雄 清水
尚吾 徳山
賀寿夫 中本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bizen Chemical Co Ltd
Original Assignee
Bizen Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bizen Chemical Co Ltd filed Critical Bizen Chemical Co Ltd
Publication of WO2016152054A1 publication Critical patent/WO2016152054A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate

Definitions

  • the present invention relates to a treatment method for preventing and / or improving pain, a pharmaceutical composition, a composition for eating and drinking, and a method for producing such a composition.
  • the pharmaceutical composition and the food and beverage composition of the present invention contain ⁇ 3 fatty acid glycerides as active ingredients.
  • Non-Patent Documents 1 and 2, and Patent Document 1 ⁇ 3 fatty acids such as ⁇ -linolenic acid (ALA), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA) contained in fish oil, algae, genetically modified plants, etc. Not only improves cardiovascular disease, improves cranial nerve function, improves immune function, but also exerts a wide range of functions such as prevention and improvement of diseases through oxidative stress suppression, and is also effective in suppressing cancer growth, etc. It is a material that has been expanded in use (Non-Patent Documents 1 and 2, and Patent Document 1).
  • ALA ⁇ -linolenic acid
  • SDA stearidonic acid
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaeno
  • ⁇ 3 fatty acids are put on the market as food materials, health food materials, cosmetic materials and pharmaceutical materials as glycerides, free fatty acids and ethyl esters, or concentrated and purified. These ⁇ 3 fatty acids are generally concentrated by combining a vacuum precision distillation method, a molecular distillation method, a chromatography method, a low-temperature solvent fractional crystallization method, a urea addition method, a silver nitrate complex formation method, and the like in a timely manner.
  • EPA ethyl ethyl ester form of EPA
  • EPA ethyl ethyl ester form of EPA
  • glycerides As they are or after concentrating and purifying ⁇ 3 fatty acids.
  • the ⁇ 3 fatty acid contained in the glyceride may be concentrated by a low-temperature solvent fractional crystallization method or concentrated by enzymatic treatment such as lipase. Fatty acid purity is limited to 70%.
  • Non-patent Document 3 glyceride ⁇ 3 fatty acids have a higher absorption rate and higher bioavailability than ethyl ester, but the details have not been elucidated.
  • free fatty acids have a high absorption rate and reactivity, they are said to cause inflammation and ulceration in the gastrointestinal tract and cause hemolysis of red blood cells when ingested for a long time.
  • prostaglandins and leukotrienes derived from fatty acids are involved in the induction of pain and the onset and chronicity of neuropathic pain.
  • omega-3 fatty acids When omega-3 fatty acids are used as active ingredients in pharmaceutical compositions and food and beverage compositions, free fatty acid type ⁇ 3 fatty acids or lower fatty acid esters of these fatty acids with ethanol, methanol, etc. are used.
  • the free fatty acid type is generally considered to induce digestive ulcer, inflammation and erythrocyte hemolysis after oral ingestion, and there is a problem that continuous ingestion is medically unsuitable.
  • the lower alcohol esters of these fatty acids with ethanol, methanol, etc. are inferior in absorption when compared with the free fatty acid type, and a large amount of intake is required, and further, bioavailability is inferior when compared with the free fatty acid type. It is said that it has problems such as being.
  • the inventors of the present invention have completed the present invention by providing a glyceride type ⁇ 3-fatty acid as an active ingredient of a preventive or therapeutic agent for pain such as pain.
  • the present invention provides the following.
  • a pharmaceutical composition comprising omega-3 fatty acid glycerides for preventing and / or treating pain, wherein the proportion of triglycerides in the omega-3 fatty acid glycerides is 70 wt% or more.
  • the omega-3 fatty acid is selected from the group consisting of ⁇ -linolenic acid (ALA), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
  • ALA ⁇ -linolenic acid
  • SDA stearidonic acid
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • the pharmaceutical composition according to Item 1 comprising a target omega-3 fatty acid, wherein the target omega-3 fatty acid accounts for 90 wt% or more of the total omega-3 fatty acid.
  • Item 3 Item 3.
  • DHA docosahexaenoic acid
  • the omega-3 fatty acid glyceride is obtained by performing a treatment selected from the group consisting of an enzymatic treatment and a chemical treatment on a substance selected from the group consisting of an omega-3 fatty acid and a lower alcohol ester thereof.
  • the pharmaceutical composition according to Item 1. Item 5)
  • Item 1 A pharmaceutical composition according to item 1, which is taken orally.
  • the pharmaceutical composition according to item 1 which is administered as an infusion.
  • the pain is arthritis, osteoarthritis, indirect rheumatism, autoimmune disorders, sudden recurrence of chronic diseases, pain from fever, and secondary pain for pain disorders or other symptoms, dysmenorrhea Pain, fibromyalgia, musculoskeletal pain, toothache, postoperative pain, familial adenomatous polyposis, pain from other neoplastic diseases, pain from COX-2 mediated symptoms, burns Item 2.
  • omega-3 fatty acid glycerides for preventing and / or treating pain, wherein the ratio of triglycerides in the omega-3 fatty acid glycerides is 60 wt% or more.
  • the omega-3 fatty acid is selected from the group consisting of ⁇ -linolenic acid (ALA), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
  • ALA ⁇ -linolenic acid
  • SDA stearidonic acid
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • the composition for eating and drinking according to Item 8 comprising a target omega-3 fatty acid, wherein the target omega-3 fatty acid accounts for 90 wt% or more of the total omega-3 fatty acid.
  • the composition for eating and drinking according to Item 9 wherein the omega-3 fatty acid is docosahexaenoic acid (DHA).
  • the omega-3 fatty acid glyceride is obtained by performing a treatment selected from the group consisting of an enzymatic treatment and a chemical treatment on a substance selected from the group consisting of an omega-3 fatty acid and a lower alcohol ester thereof.
  • the pain is arthritis, osteoarthritis, indirect rheumatism, autoimmune disorders, sudden recurrence of chronic diseases, pain from fever, and secondary pain for pain disorders or other symptoms, dysmenorrhea Pain, fibromyalgia, musculoskeletal pain, toothache, postoperative pain, familial adenomatous polyposis, pain from other neoplastic diseases, pain from COX-2 mediated symptoms, burns Item 9.
  • omega-3 fatty acids such as glyceride-type ALA, SDA, EPA, DPA, DHA, and the like, substances for inhibiting and treating pain such as pain, and compositions for eating and drinking.
  • pain refers to all categories of pain, regardless of its nature or cause, including neuropathic pain, inflammatory pain, nociceptive pain, idiopathic pain, neuralgia. Pain, orofacial pain, burn pain, chronic bone pain, low back pain, neck pain, abdominal pain, oral burning syndrome, somatic pain, visceral pain (including abdomen), fascial pain, toothache, cancer pain, chemistry Therapeutic pain, myofascial pain syndrome, complex local pain syndrome (CRPS), temporomandibular pain, traumatic pain, paroxysmal pain, surgical pain, postoperative pain, labor pain, reflex sympathetic dystrophy, brachial nerve Plexus withdrawal injury, neurogenic bladder, acute pain, musculoskeletal pain, postoperative pain, chronic pain, persistent pain, peripheral mediated pain, central mediated pain, chronic headache, tension headache, cluster headache, migraine , Associated with familial hemiplegic migraine, headache Condition, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, post-stroke
  • omega-3 fatty acid refers to an unsaturated fatty acid having a carbon-carbon double bond at the ⁇ 3 position.
  • omega-3 fatty acids include ⁇ -linolenic acid (ALA), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). It is not limited to.
  • lower alcohol ester of fatty acid refers to an ester of a fatty acid and a lower alcohol.
  • lower alcohols used for the production of lower alcohol esters of fatty acids include, but are not limited to, methanol and ethanol.
  • omega-3 fatty acid glyceride includes triglycerides, diglycerides, and monoglycerides.
  • the “omega-3 fatty acid glyceride” of the present invention is a triglyceride.
  • the proportion of triglyceride in the omega-3 fatty acid glyceride is 60 wt% or more. More preferably, it is 65% or more, still more preferably 70 wt% or more, and most preferably 80 wt% or more.
  • the target omega-3 fatty acids include ⁇ -linolenic acid (ALA), stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
  • ALA ⁇ -linolenic acid
  • SDA stearidonic acid
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • the ratio of the target omega-3 fatty acid in all the omega-3 fatty acids is 80 wt% or more.
  • the weight of the omega-3 fatty acid used in the calculation of this ratio is calculated as the weight of the omega-3 fatty acid in the weight of the omega-3 fatty acid glyceride, for example, in the case of omega-3 fatty acid glycerides.
  • the desired glyceride having a purity of ⁇ 3 fatty acid of 90 wt% or higher is synthesized by using the fatty acid or lower alcohol ester thereof as a starting material at least 90 wt% or higher as an ester with glycerin.
  • the esterification reaction can be generally obtained by a reversible reaction with lipase or a chemical synthesis reaction with acid or alkali.
  • the fatty acid of 90 wt% or higher or a lower alcohol ester thereof can be obtained by a known method (Japanese Patent Laid-Open Nos. 2000-212588 and 11-209786).
  • these lower alcohol esters are a mixture of multiple types of fatty acid esters, generally one or more methods such as vacuum precision distillation method, molecular distillation method, chromatographic method, urea addition method, silver nitrate complex method, low-temperature solvent fractional crystallization method, etc.
  • a mixture containing at least 90 wt% of the target ⁇ 3 fatty acid can be obtained by purification in combination.
  • these purification methods are merely examples and not the object of the present invention, and it is obvious that the esterification method and the concentration purification method itself are not limited.
  • the glyceride ⁇ 3 fatty acid used in the present invention is assumed to be, for example, trieicosapentaenoyl glyceride in which three molecules of EPA are bound to one molecule of glycerin. Is the same. That is, preferably, the “omega-3 fatty acid glyceride of the present invention” means a triglyceride in which only one ⁇ 3 fatty acid is bonded to one molecule of glycerin.
  • each glyceride is a mixture composed of triglyceride, diglyceride, and monoglyceride.
  • the proportion of triglyceride in the total glyceride is preferably 60 wt. % Or more, more preferably 70 wt% or more, and most preferably 80 wt% or more.
  • ⁇ 3 fatty acid glyceride refers to a composition comprising monoglyceride, diglyceride and at least 60 wt% triglyceride.
  • trieicosapentaenoyl glyceride when trieicosapentaenoyl glyceride is chemically or enzymatically synthesized from ethyl eicosapentaenoate, unreacted ethyl eicosapentaenoate, monoeicosapentaenoyl glyceride or dieicosa is synthesized.
  • pentaenoyl glyceride is present in the product, the proportion of trieicosapentaenoyl glyceride in the total glyceride is preferably at least 60 wt%.
  • a free ⁇ 3 fatty acid is used as a starting material.
  • trieicosapentaenoyl glyceride can be chemically or enzymatically synthesized by a known method.
  • the synthesis of each other fatty acid glyceride is the same (Yukihisa Tanaka, Tadashi Funada and Jiro Hirano, ester synthesis reaction by lipase, synthesis of triacylglycerol of EPA and DHA, oil chemistry, 41 (3), 563-567 (1992). And JP-A-8-40981).
  • the acid value (AV) of the trieicosapentaenoyl glyceride synthesized in this way is 5.0 or less, preferably 4.0 or less, more preferably 3.0 or less, still more preferably 2.0 or less, Preferably it is 1.0 or less.
  • the peroxide value (POV) is 10.0 or less, preferably 8.0 or less, more preferably 6.0 or less, still more preferably 4.0 or less, and most preferably 3.0 or less.
  • unpurified trieicosapentaenoyl glyceride mixture is treated by physical treatment such as adsorbent treatment such as activated clay, acid clay, activated carbon, silicic acid, activated alumina, pyrolysis treatment, molecular distillation treatment, etc. Can be reached.
  • adsorbent treatment such as activated clay, acid clay, activated carbon, silicic acid, activated alumina, pyrolysis treatment, molecular distillation treatment, etc.
  • the resulting product is added with antioxidants such as vitamin E and ascorbyl palmitate to help maintain quality.
  • Non-Patent Documents 4 and 5 When using omega-3 fatty acids, it is possible to ingest or ingest as an infusion.
  • Ethyl ester fatty acids are said to have a lower absorption rate than free fatty acids and glyceride fatty acids (Non-patent Document 3).
  • the present inventors have solved the problems of free fatty acids and ester-type ⁇ 3 fatty acids in the prior art by providing omega-3 fatty acid glycerides in which the ratio of the target omega-3 fatty acids is 90 wt% or more.
  • the present inventors have found that it exhibits pharmacological superiority and superiority as a composition for eating and drinking, and has completed the present invention.
  • Pain is an early warning system necessary to protect the body from disability and noxious stimuli.
  • chronic pain is a state in which pain is felt despite the healing of the disorder. In this case, the pain does not serve as a warning, and quality. It only reduces the of life (QOL).
  • QOL life
  • pain is roughly classified into nociceptive pain, neuropathic pain, cancer pain, and the like regardless of the type of disease. It can also be divided into acute pain and chronic pain according to the duration of pain.
  • Acute pain is a symptom of pain associated with trauma and disease caused by transient excitement of nociceptors by noxious stimuli and disappears in a few days.
  • chronic pain is regarded as substantial pain that seems to be the cause of early pain, and is caused by abnormalities in pain transmission, control, and cognitive mechanisms (Reference 1).
  • NSAIDs Non-steroidal anti-inflammatory drugs
  • COX cycloxygenase
  • neuropathic pain which is one of chronic pain, is known to be difficult to succeed with existing therapeutic agents such as NSAIDs and narcotic analgesics, and appropriate treatment from the point that the pathogenesis of pain is unknown This is a situation where it has not been possible to perform (Reference Documents 2 and 3).
  • the effectiveness and safety of existing analgesics for pain treatment are insufficient, and development of new analgesics and further elucidation of pain control mechanisms are regarded as social issues.
  • Resolvin E1 RvE1
  • Resolvin D1 RvD1
  • chemR23 a receptor for Resolvin
  • NMDA D aspartic acid
  • Resolvin D precursor 17 (R) -hydroxy-docosahexaenoic acid (17 (R) HDoHE) and aspirin-induced resolvin D1 (AT-RvD1) are very low doses of 1 mg / kg Reported that inflammatory pain can be suppressed in arthritis model mice.
  • RvD1 inhibits inflammatory pain by inhibiting the activation of TRP channels such as transient receptor potential channel (TRP) A1, TRPV3 and TRPV4, and spinal cord of RvD1.
  • TRP transient receptor potential channel
  • Intracavitary administration has been reported to be effective in preventing postoperative pain and subsequent relief of symptoms.
  • the anti-nociceptive effects of 17 (R) HDoHE, RvD1 and AT-RvD1 show significant effectiveness against mechanical stimulation rather than thermal stimulation.
  • GPCRs such as GPR32 and ALX / FPR2.
  • the possibility of involvement of other metabolites such as AT-RvD2,3,4,5 has also been suggested (reference documents 13 to 14).
  • neuroprotectin / protectin D1 also suppresses neuropathic pain by inhibiting the activation of neuropathy-induced glial cells after nerve trauma and the accompanying inflammatory response (Reference 15).
  • lipid mediators such as those described above are expected to be new therapeutic agents for inflammatory pain associated with arthritis and back pain inflammatory bowel disease.
  • the pharmaceutical composition and the food and beverage composition of the present invention contain ⁇ 3 fatty acids such as glyceride-type ALA, SDA, EPA, DPA, DHA as active ingredients.
  • the pharmaceutical composition and the edible composition of the present invention desirably have an active ingredient content of 10% by weight or more, more preferably 30% by weight or more.
  • Other known components or raw materials may be used in combination as appropriate as long as they do not interfere with the desired effects of the present invention. Examples of these include ascorbic acid, amino acids, peptides, proteins and degradation products thereof, various sugars, starches and degradation products thereof, minerals, vitamin E, tocopherol, phytosterols, polyphenols such as catechin, guava leaves, etc. and derivatives thereof Although not limited to these, it is not limited to these.
  • these concomitant substances are oil-soluble, such as ascorbyl palmitate, phytosterol, vitamin E, etc.
  • they are mixed with the omega-3 fatty acid or derivative thereof according to the present invention to form a uniform state, and ascorbic acid, amino acid
  • the dry powder is kneaded with the ⁇ 3 fat according to the present invention or a derivative thereof, or an oil containing the same to form a dispersed state, or water and appropriately
  • a surfactant can be coexisted in an emulsified state.
  • a edible composition / pharmaceutical composition comprising ⁇ 3 fat or a derivative thereof as an active ingredient is provided. Furthermore, as an aspect of the composition of the present invention, a pharmaceutical composition and a composition for eating and drinking are suitable.
  • the present invention also provides a method of treating and / or preventing a disease or disorder (eg, ulcerative colitis, nephritis, osteoporosis) that can be treated and / or prevented by administration of an effective amount of a therapeutic agent to a subject.
  • a disease or disorder eg, ulcerative colitis, nephritis, osteoporosis
  • therapeutic agent is meant a composition of the invention in combination with a pharmaceutically acceptable carrier type (eg, a sterile carrier).
  • the total pharmaceutically effective amount of orally administered therapeutic agent per dose is in the range of about 2 ⁇ g / kg / day to 1000 mg / kg / day of patient body weight, as described above. This is left to therapeutic discretion. More preferably, for the extracts of the present invention, this dose is at least 10 mg / kg / day, most preferably between about 20 mg / kg / day and about 1000 mg / kg / day for humans. Also, as a general proposition, the total pharmaceutically effective amount of the therapeutic agent administered parenterally per dose is in the range of about 0.2 ⁇ g / kg / day to 250 mg / kg / day of patient weight. As noted above, this is left to therapeutic discretion. More preferably, for the extract of the invention, this dose is at least 1 mg / kg / day, most preferably between about 5 mg / kg / day and about 25 mg / kg / day for humans.
  • the therapeutic agent can be oral, rectal, parenteral, intracisternally, intravaginally, intraperitoneally, topically (such as by powder, ointment, gel, instillation, or transdermal patch), oral or oral or It can be administered as a nasal spray.
  • a typical route of administration of the pharmaceutical composition of the present invention is oral administration.
  • “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulant or any type of formulation aid.
  • the therapeutic agent of the present invention is also appropriately administered by a sustained release system.
  • sustained release therapeutic agents are oral, rectal, parenteral, intracisternally, intravaginally, intraperitoneally, topically (powder, ointment, gel, infusion, or transdermal patch) Etc.), or as an oral or nasal spray.
  • “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulant or any type of formulation adjuvant.
  • parenteral refers to modes of administration including intravenous and intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injections and infusions.
  • the therapeutic agent of the present invention is also appropriately administered by a sustained release system.
  • sustained release therapeutic agents include suitable polymer materials (eg, semipermeable polymer matrices in the form of molded articles (eg, films or microcapsules)), suitable hydrophobic materials (eg, in acceptable quality oils). Or an ion exchange resin, and poorly soluble derivatives (eg, poorly soluble salts).
  • Sustained release matrices include polylactide (US Pat. No. 3,773,919, EP 58,481), a copolymer of L-glutamic acid and ⁇ -ethyl-L-glutamate (Sidman et al., Biopolymers 22: 547-556 (1983)). ), Poly (2-hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl Acetate (Langer et al., Ibid) or poly-D-(-)-3-hydroxybutyric acid (EP133,988).
  • polylactide US Pat. No. 3,773,919, EP 58,481
  • a copolymer of L-glutamic acid and ⁇ -ethyl-L-glutamate Sidman et al., Biopolymers 22: 547
  • Sustained release therapeutic agents also include the therapeutic agents of the present invention entrapped in liposomes (generally, Langer, Science 249: 1527-1533 (1990); Treat et al., Liposomes in the Therapeutic Diseases and Cancers, Cancer -See Berstein and Fiddler (eds.), Liss, New York, pages 317-327 and 353-365 (1989)).
  • Liposomes containing therapeutic agents can be prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.
  • liposomes are small (about 200-800 cm) unilamellar type, where the lipid content is greater than about 30 mol% cholesterol and the selected proportion is adjusted for optimal therapeutic agents.
  • the therapeutics of the invention can be delivered by a pump (Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14: 201 (1987); Buchwald et al., Surgary 88: 507 ( 1980); Saudek et al., N. Engl. J. Med. 321: 574 (1989)).
  • the therapeutic agent is toxic to the recipient in the desired degree of purity, in a pharmaceutically acceptable carrier, i.e. the dosage and concentration used. It is formulated by mixing in a unit dosage injectable form (solution, suspension or emulsion) with one that is not and compatible with the other ingredients of the formulation.
  • a unit dosage injectable form solution, suspension or emulsion
  • the formulation preferably does not include oxidation and other compounds known to be harmful to therapeutic agents.
  • a formulation is prepared by contacting the therapeutic agent uniformly and intimately with a liquid carrier or a finely divided solid carrier or both.
  • the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient.
  • carrier vehicles include water, saline, Ringer's solution, and dextrose solution.
  • Nonaqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as are liposomes.
  • the carrier suitably contains trace amounts of additives such as substances that enhance isotonicity and chemical stability. Such substances are not toxic to the recipient at the dosages and concentrations used, such as phosphate, citrate, succinate, acetic acid and other organic acids or their salts.
  • Buffering agents such as ascorbic acid; low molecular weight (less than about 10 residues) polypeptides (eg, polyarginine or tripeptides); proteins such as serum albumin, gelatin or immunoglobulins; polyvinylpyrrolidone Hydrophilic polymers such as: amino acids such as glycine, glutamic acid, aspartic acid or arginine; monosaccharides, disaccharides and other carbohydrates including cellulose or derivatives thereof, glucose, mannose or dextrin; chelating agents such as EDTA Sugar sugars such as mannitol or sorbitol Lumpur; counterions such as sodium; and / or polysorbate include nonionic surfactants such as poloxamers or PEG.
  • polypeptides eg, polyarginine or tripeptides
  • proteins such as serum albumin, gelatin or immunoglobulins
  • polyvinylpyrrolidone Hydrophilic polymers such as: amino acids such as glycine, gluta
  • the therapeutic agent is typically formulated in such a vehicle at a pH of about 6-9 at a concentration of about 10 mg / ml to 1000 mg / ml, preferably 50-1000 mg / ml. It is understood that by using the specific excipients, carriers or stabilizers described above, salts are formed.
  • Any drug to be used for therapeutic administration may be in a state that does not contain a living organism / virus other than the virus as an active ingredient, that is, in a sterile state. Aseptic conditions are easily achieved by filtration through sterile filtration membranes (eg, 0.2 micron membranes).
  • the therapeutic agent is placed in a container having a sterile access port, for example, an intravenous solution bag or vial with a stopper puncturable with a hypodermic needle.
  • Treatment agents are usually stored in unit dose or multi-dose containers, such as sealed ampoules or vials, as aqueous solutions or lyophilized formulations for reconstitution.
  • a lyophilized formulation a 10 ml vial is filled with 5 ml of a sterile filtered 5% (w / v) aqueous therapeutic agent and the resulting mixture is lyophilized.
  • the lyophilized therapeutic agent is reconstituted with bacteriostatic water for injection to prepare an infusion solution.
  • the present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more components of the therapeutic agent of the present invention.
  • a notice of the form prescribed by a government agency that regulates the manufacture, use or sale of a medicinal product or biological product may be attached to such a container, and this notice may be attached to the government regarding the manufacture, use or sale for human administration. Represents institutional approval.
  • the therapeutic agent may be used in combination with other therapeutic compounds.
  • the therapeutic agent of the present invention can be administered alone or in combination with other therapeutic agents.
  • the combinations can be administered, for example, either simultaneously as a mixture; simultaneously or concurrently but separately; or over time. This includes the presentation that the combined agents are administered together as a therapeutic mixture, and also the procedure where the combined agents are administered separately but simultaneously, eg, through separate intravenous lines to the same individual . Administration in combination further includes separate administration of one of the compounds or agents given first, followed by the second.
  • the above-mentioned extract may be used as it is, but this is further fractionated to obtain a fraction containing an active ingredient at a higher concentration. It may be used.
  • composition for eating and drinking is a composition for eating and drinking. That is, a pharmaceutical composition or a composition for eating or drinking containing an omega-3 fatty acid or a derivative thereof obtained as described above as an active ingredient is used as it is as a liquid, gel or solid food, for example, juice, soft drink , Coffee, tea, Japanese tea, oolong tea, vegetable juice, natural fruit juice, milk drink, milk, soy milk, sports drink, near-water drink, nutritional drink, coffee drink, cocoa, soup, dressing, mousse, jelly, yogurt, Pudding, sprinkles, infant formula, processed milk, sports drink, energy drink, cake mix, bread, pizza, pie, crackers, biscuits, cake, cookies, spaghetti, macaroni, pasta, udon, buckwheat, ramen, candy, soft candy , Gum, chocolate, rice cake, potato chips Powdered or liquid dairy products such as snacks, snacks, ice cream, sorbets, creams, cheese, powdered milk, condensed milk
  • the blending amount of the omega-3 fatty acid of the present invention or a derivative thereof in these foods or food-drinking compositions is difficult to define uniformly depending on the type and state of the food or composition, but is about 0.01 to 50 % By weight, more preferably 0.1 to 30% by weight. If the blending amount is less than 0.01% by weight, the desired effect by oral intake is small, and if it exceeds 50% by weight, the flavor may be impaired or the food may not be prepared depending on the type of food.
  • the omega-3 fatty acid or derivative thereof of the present invention may be used for food as it is.
  • a desired ⁇ 3 fatty acid ester, glycerin, and a hydroxide of an alkali metal or alkaline earth metal are prepared.
  • the ⁇ 3-fatty acid ester of the substrate is an ester condensation compound of ALA, SDA, EPA, DPA, DHA, a compound obtained by ester condensation of a carboxyl group substituted with these fatty acids, and ethanol is used as the alcohol to be condensed.
  • ethanol is used as the alcohol to be condensed.
  • hydroxides with alkali metals and alkaline earth metals calcium hydroxide, sodium hydroxide, potassium hydroxide, etc., potassium hydroxide is preferred.
  • fatty acid esters, glycerin, and potassium hydroxide are heated and stirred.
  • the heating device is set to a range of 110 ° C. to 130 ° C. using an oil bath, for example, and further, a decompression device such as a vacuum pump is used to reduce the pressure to 5 mmHg or less. Pressure is preferred.
  • the upper organic phase in which the reactant is dissolved is recovered and the solvent is distilled off using a rotary evaporator.
  • the pressure in the reduced pressure is preferably 150 mmHg or less, but may be higher if the solvent can be distilled off.
  • the temperature at the time of distilling off the solvent is in a range where the oxidation of the reaction product does not proceed extremely, and is 20 ° C. to 40 ° C., preferably 30 ° C.
  • the reaction product is purified by various purification methods such as column chromatography to obtain the desired tridocosahexaenoyl glyceride.
  • Example 1 Synthesis of ⁇ 3 fatty acid glyceride from ethyl ester
  • DHA ethyl ester Specific examples for the preparation of tridocosahexaenoyl glyceride using DHA ethyl ester as a starting material are shown below: 45 g (0.126 mol) of DHA ethyl ester (purity: 97%), 4.0 g (0.043 mol) of glycerin, and 0.6 g (0.011 mol) of potassium hydroxide were placed in a reaction vessel. The triglyceride synthesis reaction was carried out by reducing the pressure to 5 mmHg by means of a vacuum pump in an oil bath and stirring for 24 hours.
  • the heat-treated reaction product After the heat-treated reaction product is cooled to room temperature, it is transferred to a separatory funnel, and water, hexane, and ethanol are added to separate it into two layers by liquid-liquid distribution. Glycerin and potassium hydroxide were removed.
  • the solvent is distilled off at a pressure of 150 mmHg and a temperature of 30 ° C. using a rotary evaporator to obtain 34.5 g of the reaction product (tridocosahexahexa Enoyl glyceride: 20.7 g, diglyceride: 9.3 g, monoglyceride: 3.4 g, free fatty acid: 0.7 g, unreacted DHA ethyl ester: 0.03 g).
  • the reaction product was purified by tridocosahexaenoyl glyceride by silica gel column chromatography using a hexane-diethyl ether mixture as a mobile phase, added with activated carbon, stirred, and filtered to give an acid value of 1 or less and a peroxide value of 3
  • an omega-3 fatty acid glyceride having 65% by weight of tridocosahexaenoyl glyceride and a DHA composition ratio (ratio of DHA in the whole omega-3 fatty acid) of 96% was obtained.
  • Example 2 Synthesis of ⁇ 3 fatty acid glyceride from methyl ester
  • the synthesis reaction was performed.
  • reaction product after the heat treatment is cooled to room temperature, then transferred to a separatory funnel, water and hexane are added, and ethanol is further separated into two layers by liquid-liquid distribution. Glycerol and potassium hydroxide were removed.
  • the solvent is distilled off at a pressure of 150 mmHg and a temperature of 30 ° C. using a rotary evaporator to obtain 34.5 g of the reaction product (tridocosahexahexa Enoyl glyceride: 21.1 g, diglyceride: 8.3 g, monoglyceride: 4.1 g, free fatty acid: 0.8 g, unreacted DHA methyl ester: 0.03 g).
  • the reaction product was purified by tridocosahexaenoyl glyceride by silica gel column chromatography using a hexane-diethyl ether mixture as a mobile phase, added with activated clay, stirred and filtered to give an acid value of 1 or less and a peroxide value of 3
  • omega-3 fatty acid glycerides having 78% by weight of tridocosahexaenoyl glyceride and 98% DHA composition ratio (ratio of DHA in the whole omega-3 fatty acids) were obtained.
  • Example 3 Synthesis of ⁇ 3 fatty acid glyceride from fatty acid
  • DHA purity: 97%)
  • 4.5 g (0.049 mol) of glycerin and 2.25 g of Lipozyme RMIM (Novo Nordisk A / S Corp. Denmark) were placed in a reaction vessel at 60 ° C.
  • a triglyceride synthesis reaction was performed by reducing the pressure to 5 mmHg with a vacuum pump in a hot water bath and shaking for 48 hours.
  • reaction product after the shaking reaction was transferred to a separatory funnel, a diethyl ether-ethanol (1: 1) solution was added, and the reaction mixture was separated into two layers by liquid-liquid distribution to stop the reaction. Unreacted glycerin was removed by discarding the lower aqueous phase.
  • the solvent was distilled off at a pressure of 150 mmHg and a temperature of 30 ° C. using a rotary evaporator to obtain the reaction product.
  • the reaction product contains 81% of tridocosahexaenoyl glyceride and 19% of diglyceride, and this was purified by tridocosahexaenoyl glyceride by silica gel column chromatography using a hexane-diethyl ether mixture as a mobile phase.
  • Example 4 tail flick test
  • the anti-nociceptive effect of DHA on heat stimulation was tested.
  • Anti-nociceptive action against heat stimulation was evaluated by tail-flick test. Mice were placed on a tail-flick type analgesic effect measuring device (MK-330B, Muromachi Kikai, Tokyo, Japan), radiant heat was applied to the dorsal side of the tail, and the latency until the tail was moved was measured. The intensity of the thermal stimulation was adjusted so that the tail was moved between 2.5 and 3 seconds after the heat was applied, and was used as a reference value for the response latency (baseline latency). Response latencies were measured 30, 60, and 120 minutes after DHA administration.
  • Example 1 Administration of tridocosahexaenoyl glyceride prepared in Example 1 increased the response latency in a dose-dependent manner, and a peak of action was observed 60 minutes after administration. Similarly, the curve area of the tridocosahexaenoyl glyceride administration group was significantly increased compared to the control group and the DHA ethyl group. Compared to DHA ethyl, its action was stronger.
  • Example 5 Acetic acid rising test
  • Mice were transferred from home cages to new cages one by one and allowed to acclimate for 1 hour, followed by intraperitoneal injection of 0.6% (v / v) acetic acid (Wako, 10 mg / kg) for 30 minutes The number of times was measured.
  • mice were transferred one by one from the home cage to a new cage and allowed to acclimate to the environment for 1 hour, and then 10 mL of formalin 5% was administered subcutaneously to the right hind footpad of the mouse. The total time of licking, biting, and flinging of the administration site was measured in seconds and evaluated. Pain behavior was measured for 30 minutes between 0-10 minutes (early phase) and 10-30 minutes (late phase) after formalin was administered.
  • Example 7 Test in chronic inflammatory pain model mouse
  • the chronic inflammatory pain model was prepared by administering 0.5 mg / kg Freund's complete adjuvant (CFA) into the right hind footpad of mice.
  • CFA Freund's complete adjuvant
  • physiological saline was administered.
  • a chronic inflammatory pain model a mouse which was subjected to foot thickening and pain evaluation, and had inflammation of the foot, mechanical allodynia and thermal hyperalgesia from 1 day after CFA administration was used.
  • Digital calipers Sa Measurement, Niigata, Japan
  • the mouse was placed on a metal mesh and allowed to adapt for 60 minutes with a transparent plastic case covered. After confirming the disappearance of spontaneous movement, touch test filament (Touch-Test (R) Sensory E) The test was started with 0.16 g of the filament (Valators) (North Coast Medical Inc, CA, USA). The filament was pressed vertically against the ventral center of the hind limb of the mouse until it was bent slightly, and the escape response to the stimulus for 6 seconds was observed. The operation of applying stimulation with this filament was repeated 10 times, and the number of times of showing an escape reaction was recorded.
  • touch test filament Touch-Test (R) Sensory E
  • the test was started with 0.16 g of the filament (Valators) (North Coast Medical Inc, CA, USA). The filament was pressed vertically against the ventral center of the hind limb of the mouse until it was bent slightly, and the escape response to the stimulus for 6 seconds was observed. The operation of applying stimulation with this filament was repeated 10 times, and the number of times of showing an escape reaction was recorded.
  • the evaluation of escape response to thermal stimulation was performed as follows.
  • the mouse was placed in a plastic case on the glass floor and allowed to adapt for 3 hours. After confirming the disappearance of spontaneous movement, radiant heat is applied from the bottom of the glass floor to the ventral side of the hind limb of the mouse using the planter test (Ugo Basile, Comerio, Italy), and the hind limb is raised.
  • the reaction latency (pWL) until showing an escape response was recorded. In order to prevent tissue damage, the measurement time was set to a maximum of 20 seconds.
  • the present invention provides a therapeutic method for preventing and / or improving pain, a pharmaceutical composition, a composition for eating and drinking, and a method for producing such a medicine and a composition for eating and drinking.
  • Reference 1 Woolf J. et al. , What is this thing called pain? , J .; Clin. Invest. , 120, 3742-3744 (2010).
  • Reference 2 Zeilhofer H. U. Brune K. , Analytical Strategies Beyond the Inhibition of Cyclooxygenes. , Trends Pharmacol. Sci. 27, 467-474 (2006).
  • Reference 3 Woolf C.M. J. et al. , Mu and delta opioid receptors diver. , Cell, 137, 987-988 (2009).
  • Reference 4 Nakamoto, K .; Nishinaka, T .; Mankura, M .; Fujita-Hamabe, W .; , Tokuyama, S .; , 2010. Antigenic effectives of docosahexaneic acid against variant pain stimuli in mice. Biol Pharm Bull. 33, 1070-2.
  • Reference 5 Nakamoto, K .; Nishinaka, T .; , Ambo, A .; Mankura, M .; Kasuya, F .; , Tokuyama, S .; , 2011. Possible involution of beta-endorphin in docosahexaenoic acid-induced antinoction. Eur J Pharmacol. 666, 100-4.
  • Reference 6 Nakamoto, K .; Nishinaka, T .; , Matsumoto, K .; Kasuya, F .; Mankura, M .; , Koyama, Y .; , Tokuyama, S .; 2012. Involvement of the long-chain fatity acid receptor GPR40 as a novel pain regulatory system. Brain Res. 1432, 74-83.
  • Reference 7 Nakamoto K, Nishinaka T, Sato N, Mankura M, Koyama Y, Kasuya F, Tokyoyama S. Hypothalamic GPR40 signaling activated by free long chain fatity acids suppresses CFA-induced inflammatory chronic pain. PLoS One. 2013 Dec 12; 8 (12): e81563.
  • Reference 8 Lu Y, Zhao LX, Cao DL, Gao YJ. , Spinal injection of docosahexaenoic acid attendants carriageenan-induced inflammatory pain through microflamation-mediated neuroinflammation. Neuroscience. 2013 Jun 25; 241: 22-31.
  • Reference 9 Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from foil oil triacylycerols or fishoil etheresters co-inged with whistle. Biochem Biophys Res Commun. 1988; 156: 960-3.
  • Reference 10 Serhan, CN.
  • Novell eicosanoid and docosanoid mediators resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Meta Care, 2005; 8: 115-21.
  • Reference 11 Schwab, JM, Chiang, N, Arita, M & Serhan, CN.
  • Resolvin E1 and protectionin D1 activate inflation-resolution programs. Nature, 2007; 447: 869-74.
  • Reference 12 Xu, ZZ, Zhang, L, Liu, T, Park, JY, Berta, T, Yang, R, Serhan, CN & Ji, RR. Resolvins RvE1 and RvD1 attendant information pain pain central and peripheral actions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions selon lesquelles des problèmes liés aux acides gras ω3 de type libre ou aux acides gras ω3 de type ester peuvent être surmontés. La présente invention concerne une composition médicinale et une composition comestible pour la prévention et/ou le traitement de la douleur, chaque composition contenant des glycérides d'acides gras ω3, le rapport des triglycérides dans les glycérides d'acides gras ω3 étant égal ou supérieur à 60 % en poids. L'invention concerne également un procédé pour la prévention et/ou le traitement de la douleur à l'aide de ladite composition médicinale ou de ladite composition comestible.
PCT/JP2016/001259 2015-03-26 2016-03-08 Effets de prévention et d'atténuation de la douleur du glycéride d'acide gras ω3 Ceased WO2016152054A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015065025 2015-03-26
JP2015-065025 2015-03-26

Publications (1)

Publication Number Publication Date
WO2016152054A1 true WO2016152054A1 (fr) 2016-09-29

Family

ID=56979015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/001259 Ceased WO2016152054A1 (fr) 2015-03-26 2016-03-08 Effets de prévention et d'atténuation de la douleur du glycéride d'acide gras ω3

Country Status (1)

Country Link
WO (1) WO2016152054A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019244140A1 (fr) * 2018-06-21 2019-12-26 マルハニチロ株式会社 Agent destiné à maintenir et à protéger la fonction rénale, et procédé d'évaluation de l'effet de celui-ci
JP2020002125A (ja) * 2018-06-21 2020-01-09 マルハニチロ株式会社 腎機能維持及び保護剤、並びに、その効果評価方法
WO2021074118A1 (fr) * 2019-10-15 2021-04-22 Hermes Arzneimittel Gmbh Compositions liquides d'acides gras oméga 3 pour une administration orale directe
EP3744323A4 (fr) * 2018-01-26 2021-12-29 Ajinomoto Co., Inc. Composition pour prévention ou amélioration de la douleur nociceptive

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129216A (ja) * 1985-11-28 1987-06-11 Nippon Suisan Kaisha Ltd 脂肪輪液
JPS62163669A (ja) * 1986-01-14 1987-07-20 Taiyo Fishery Co Ltd エイコサペンタエン酸含有スプレツド食品
JPH05331105A (ja) * 1991-07-24 1993-12-14 Agency Of Ind Science & Technol ドコサヘキサエン酸トリグリセリド及びその製造法
JPH0672959A (ja) * 1991-03-28 1994-03-15 Agency Of Ind Science & Technol エイコサペンタエン酸トリグリセリド及びその製造法
JP2000212588A (ja) * 1999-01-21 2000-08-02 Ikeda Shokken Kk 高度不飽和脂肪酸含有グリセリドの製造方法
JP2009520824A (ja) * 2005-12-20 2009-05-28 セネストラ エルエルシー オメガ３脂肪酸製剤
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US20140050807A1 (en) * 2010-09-17 2014-02-20 Harry J. Leighton Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129216A (ja) * 1985-11-28 1987-06-11 Nippon Suisan Kaisha Ltd 脂肪輪液
JPS62163669A (ja) * 1986-01-14 1987-07-20 Taiyo Fishery Co Ltd エイコサペンタエン酸含有スプレツド食品
JPH0672959A (ja) * 1991-03-28 1994-03-15 Agency Of Ind Science & Technol エイコサペンタエン酸トリグリセリド及びその製造法
JPH05331105A (ja) * 1991-07-24 1993-12-14 Agency Of Ind Science & Technol ドコサヘキサエン酸トリグリセリド及びその製造法
JP2000212588A (ja) * 1999-01-21 2000-08-02 Ikeda Shokken Kk 高度不飽和脂肪酸含有グリセリドの製造方法
JP2009520824A (ja) * 2005-12-20 2009-05-28 セネストラ エルエルシー オメガ３脂肪酸製剤
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US20140050807A1 (en) * 2010-09-17 2014-02-20 Harry J. Leighton Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAZUO NAKAMOTO ET AL.: "Antinociceptive Effect of Docosahexaenoic Acid (DHA) through Long Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40", YAKUGAKU ZASSHI, vol. 134, no. 3, 1 March 2014 (2014-03-01), pages 397 - 403 *
LAWSON D. LARRY ET AL.: "HUMAN ABSORPTION OF FISH OIL FATTY ACIDS AS TRIACYLGLYCEROLS, FREE ACIDS, OR ETHYL ESTERS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 152, no. 1, 15 April 1988 (1988-04-15), pages 328 - 335, XP055316822 *
NAKAMOTO,KAZUO ET AL.: "Antinociceptive Effects of Docosahexaenoic Acid against Various Pain Stimuli in Mice", BIOL. PHARM. BULL., vol. 33, no. 6, 2010, pages 1070 - 1072, XP008136227 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744323A4 (fr) * 2018-01-26 2021-12-29 Ajinomoto Co., Inc. Composition pour prévention ou amélioration de la douleur nociceptive
US11730713B2 (en) 2018-01-26 2023-08-22 Ajinomoto Co., Inc. Composition for preventing or improving nociceptive pain
WO2019244140A1 (fr) * 2018-06-21 2019-12-26 マルハニチロ株式会社 Agent destiné à maintenir et à protéger la fonction rénale, et procédé d'évaluation de l'effet de celui-ci
JP2020002125A (ja) * 2018-06-21 2020-01-09 マルハニチロ株式会社 腎機能維持及び保護剤、並びに、その効果評価方法
GB2590868A (en) * 2018-06-21 2021-07-07 Maruha Nichiro Corp Kidney function maintenance and protection agent, and method for evaluating effect thereof
JP7013416B2 (ja) 2018-06-21 2022-01-31 マルハニチロ株式会社 腎機能維持及び保護剤、並びに、その効果評価方法
WO2021074118A1 (fr) * 2019-10-15 2021-04-22 Hermes Arzneimittel Gmbh Compositions liquides d'acides gras oméga 3 pour une administration orale directe

Similar Documents

Publication Publication Date Title
JP5443979B2 (ja) 新規のロイコトリエン受容体アンタゴニスト
EP0342956A2 (fr) Utilisation de l'acide phytique ou de ses sels pour le traitement de l'hyperlipémie, de l'obésité et de maladies apparentées
WO2001010989A1 (fr) Compositions a base de matiere grasse
EP1481675A1 (fr) Agents destines a elever la temperature corporelle
WO2016152054A1 (fr) Effets de prévention et d'atténuation de la douleur du glycéride d'acide gras ω3
TWI389697B (zh) Improve the composition of lipid metabolism
US20220273600A1 (en) Lithium salts of n-substituted glycine compounds and uses thereof
JP2010132631A (ja) カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
CN1796388B (zh) 芝麻素/异芝麻素组合物
JP6996755B2 (ja) ω３およびω６不飽和脂肪酸酸化物の製造方法
JPS63104917A (ja) コレステロール低下または上昇抑制剤
US7579374B2 (en) Agent for improving bone metabolism
TW202110427A (zh) 肝臟功能改善用組成物
JP2010184914A (ja) プロトンポンプ阻害活性を有する組成物
CN107922308B (zh) 新型甘油三酯及其用途
KR20140095167A (ko) 호노키올 및 마그놀올을 유효성분으로 하는 지방간 질환 예방 또는 치료용 조성물
JP2009173556A (ja) プロスタグランジンｅ２受容体、ｅｐ４アゴニストおよびそれを含有する組成物
JP7016071B2 (ja) 食欲抑制剤
EP2484358B1 (fr) Agent pour inhiber la diminution des graisses viscérales chez des patients atteints de la maladie de parkinson
JP4152818B2 (ja) 共役脂肪酸を有効成分とする高血圧予防剤およびその用途
JP5099946B2 (ja) 抗腫瘍組成物の製造方法
WO2015137500A1 (fr) Agent anti-obésité
JP7781386B2 (ja) 脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤
KR101559655B1 (ko) 미리세틴을 유효성분으로 포함하는 췌장 리파아제 저해용 조성물
JP2008038011A (ja) 高純度リン脂質の製造法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16767964

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16767964

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP